Every time a pharma professional submits a query to a public AI API containing an unpublished clinical trial result, a competitive pipeline analysis, or a regulatory strategy document, that data may be logged, stored, and processed by a third-party provider whose terms of service were written to serve a global consumer and enterprise market, not a regulated pharmaceutical organisation. A McKinsey survey of 300 executives, investors, and government officials found that 71% characterise sovereign AI as an existential concern or strategic imperative. [1] In pharma, where the data involved includes material non-public clinical information, commercially sensitive pipeline intelligence, and patient data from clinical programmes, that 71% would likely be higher.
The sovereign cloud market is expected to grow from $123 billion in 2024 to $258 billion by 2027, driven largely by regulated industries and public sector organisations whose data governance obligations cannot be satisfied by standard public cloud contracts. [4][7] For pharma organisations deploying AI across clinical, regulatory, and commercial functions, the question is not whether to pursue private AI deployment. It is which data requires private deployment and which deployment model is appropriate for each use case. Pienomial's Knolens platform is built from the architecture up for private AI platform deployment, including on-premise, sovereign cloud, and air-gapped configurations.[9]
1. The Three Deployment Models: What They Actually Mean
Three deployment models are available for enterprise AI, and the distinctions between them are more important than most procurement processes acknowledge.[6]
Public cloud AI: Queries are sent to a third-party API. The provider processes the query using shared infrastructure and returns a response. Data handling depends on the provider's terms of service. Zero data retention policies reduce risk but do not eliminate it, as query logging for security monitoring and abuse detection may still occur, and legal obligations under laws such as the US CLOUD Act create extraterritorial access risk even for data stored in non-US facilities.
Private cloud AI: The AI model is accessed via API but runs on infrastructure dedicated to the organisation, whether through a dedicated cloud tenant, a hyperscaler sovereign region, or a managed private cloud. Data does not flow to a shared model. Third-party access is contractually restricted. The risk reduction is meaningful but not absolute: the cloud provider retains administrative access to infrastructure, and legal sovereignty depends on the jurisdiction of the provider and the infrastructure, not simply on the contract terms.
Air-gapped or on-premise AI: The AI platform runs entirely within the organisation's own physical or virtual infrastructure. No data is transmitted outside the organisational network boundary. No third-party API dependencies exist for core AI operations. This is the only deployment model that guarantees zero data exfiltration risk. AWS has invested €7.8 billion in the AWS European Sovereign Cloud, providing a hyperscaler-grade private cloud option for EU-regulated organisations requiring data residency and operational autonomy. [3] However, true on-premise deployment goes further, with no external network dependency at all.
2. What Pharma Data Cannot Safely Leave the Organisation
Four categories of pharma data create specific legal, regulatory, and competitive risk when transmitted to public AI APIs, and each category requires a different risk assessment framework.[5]
Category 1, Unpublished clinical trial results: Material non-public information under SEC rules for publicly traded pharma companies. Disclosure of MNPI to a third-party AI provider, even inadvertently through a query prompt containing unpublished efficacy or safety results, may constitute MNPI breach with legal consequences.
Category 2, Regulatory strategy documents: Competitive intelligence risk. Regulatory strategy documents containing pipeline priorities, submission timelines, and negotiation positions are among the most commercially sensitive assets a pharma organisation holds. Processing these through an API whose provider may use prompt data for model training, even under a zero-training contractual carve-out that is difficult to verify or enforce, creates an IP exposure risk.
Category 3, Pipeline compound information: Intellectual property risk. Novel compound structures, mechanisms of action, and synthesis routes transmitted to external AI services create prior disclosure risk that may affect patent validity in some jurisdictions.
Category 4, Patient data incorporated in clinical analysis: HIPAA in the US and GDPR in the EU impose strict obligations on the transmission of health information to third parties. Even de-identified data carries re-identification risk when processed by AI systems that have access to large external datasets for potential cross-referencing.[6]
3. The Regulatory and Legal Framework for Pharma AI Data
The regulatory framework governing pharma AI data deployment is a patchwork of healthcare privacy law, financial regulation, IP law, and emerging AI-specific regulation, and the obligations are stricter than most legal reviews of public AI API terms of service acknowledge.[2]
SEC MNPI rules apply to material non-public information, which includes unpublished clinical trial results, regulatory approval outcomes, and pipeline acquisition activity. Transmitting MNPI to an external AI provider creates disclosure risk that is not neutralised by the provider's data handling policies. The test for MNPI disclosure is not whether the data was retained by the provider, but whether it was transmitted to a party outside the issuer's information control structure.
FDA 21 CFR Part 11 applies to electronic records and electronic signatures in FDA-regulated processes. AI systems used to generate or inform content for regulatory submissions, clinical data analysis, or quality management must operate in controlled, validated environments with audit trails. Public AI APIs cannot satisfy Part 11 validation requirements without substantial additional controls that most deployments do not include.
EU GDPR Article 46 restricts transfers of personal data to non-EEA countries without adequate safeguards. Standard contractual clauses with AI providers may be insufficient for health data given the sensitivity classification under GDPR Article 9. The evolving interpretation of adequacy decisions and the continuing uncertainty around US-EU data transfer mechanisms makes reliance on contractual safeguards alone legally fragile for EU clinical data.[6]
The EU AI Act, which entered into force in 2024 with phased implementation through 2026, classifies AI systems used in clinical decision support, medical device functionality, and certain research applications as high-risk, imposing requirements for transparency, human oversight, and data governance that public cloud deployment models do not automatically satisfy.[2]
4. Sovereign Cloud: Definition and When It Is Required
Sovereign cloud refers to cloud infrastructure that operates within a specific national jurisdiction, under local data protection law, with local operational control and limited extraterritorial legal exposure. The sovereign cloud market is growing at approximately 27% year-on-year, with spending expected to reach $258 billion by 2027. [7] Both AWS and Microsoft launched EU-specific sovereign cloud offerings in 2025, specifically targeting regulated industries with data residency, operational autonomy, and encryption key management requirements.[3][4]
Sovereign cloud is required or strongly indicated for pharma organisations in four situations: when EU clinical data processing must remain within EU borders under GDPR Article 46 and data localisation mandates; when government-funded research carries contractual data localisation requirements; when market-specific data protection laws apply, including China's Data Security Law, India's Digital Personal Data Protection Act, and similar national frameworks; and when procurement requirements for public sector pharma contracts specify sovereign infrastructure.[5]
The important distinction: sovereign cloud satisfies data residency requirements. It does not automatically satisfy operational sovereignty, the requirement that the organisation retains full control over data access, encryption keys, and processing decisions, without the cloud provider being able to respond to extraterritorial legal requests for data access. Operational sovereignty requires both data residency and contractual or technical controls that limit the provider's own access to the data. Microsoft's EU sovereign cloud acknowledges residual legal risk under the US CLOUD Act, which is not fully resolved by data residency alone.[4]
5. Air-Gapped Deployment: When and How
Air-gapped deployment represents the highest level of data protection available: a system with no network connection to any external environment. Required data enters and exits via controlled media only. No external API calls are made during AI operations. The system cannot be accessed remotely by the vendor or any external party.
Air-gapped deployment is required for pharma organisations handling classified government-funded research data, CBRN-adjacent compound information, and the most sensitive categories of unpublished clinical data. It is also increasingly used in financial services and defence-adjacent life sciences organisations where competitive intelligence about pipeline compounds represents a strategic asset of the highest sensitivity.[8]
The practical constraints of air-gapped deployment: knowledge layer updates must be transferred via controlled media rather than automated network feeds, which reduces the update frequency of the intelligence layer. Model updates must be similarly transferred manually. Integration with external data sources is not possible without physically bringing data across the air gap under controlled conditions. For most pharma AI use cases, these constraints make fully air-gapped deployment appropriate for high-sensitivity enclaves rather than the primary enterprise AI environment. A private cloud with strict egress controls, no external API dependencies, and comprehensive audit logging satisfies most pharma data governance requirements without the operational overhead of a fully air-gapped system.[9]
6. LLM-Agnostic Architecture as the Private Deployment Enabler
The most significant technical barrier to private AI deployment for pharma organisations is that most enterprise AI platforms are built around a cloud-hosted LLM, GPT-4, Claude, Gemini, or similar, that cannot be deployed on-premise. This creates a structural conflict: the organisation wants private deployment, but the AI capability that makes the platform useful requires an external API call.[1]
The LLM-agnostic solution separates the knowledge layer, the governed enterprise knowledge graph containing all clinical, regulatory, and commercial intelligence, from the inference layer, the model that generates natural language outputs from retrieved facts. With a LLM agnostic AI platform architecture, the on-premise deployment uses an open-weight model such as Llama, Mistral, or Falcon, deployed entirely within the organisational network, with the knowledge graph providing the governed factual foundation. No external API call is required for either retrieval or generation.[9]
This architecture delivers the full intelligence capability of the platform, including clinical trial landscape analysis, competitive intelligence, regulatory precedent synthesis, and HEOR evidence synthesis, without transmitting any organisational data outside the network boundary. The knowledge layer is updated via controlled data ingestion pipelines that can themselves be configured for air-gapped operation. The private AI platform is not a degraded version of the cloud-hosted platform. It is the same capability, deployed in a different security context.
7. Data Classification: The Foundation of Private Deployment Decisions
Private AI deployment decisions should be driven by data classification rather than by a single organisation-wide policy. Not all pharma data requires the same level of protection, and requiring private deployment for all AI use cases creates unnecessary operational overhead while potentially missing the data that genuinely requires isolation.[6]
A practical pharma AI data classification framework has four tiers. Class 1, public data: published literature, approved drug labels, public regulatory guidance. No private deployment requirement. Public AI APIs are appropriate and efficient. Class 2, internal data: internal reports, pre-publication analyses, commercial data not yet publicly disclosed. Private cloud deployment recommended. No transmission to public APIs. Class 3, confidential data: unpublished clinical results, pipeline information, regulatory strategy, competitive intelligence. On-premise deployment required. Strict access controls and audit trail for all AI processing. Class 4, restricted data: MNPI, patient data containing re-identification risk, classified government research, the most sensitive competitive intelligence. Air-gapped or fully isolated deployment. Legal review before any AI processing. No third-party involvement.
8. Governance Framework for Private AI Deployment
Private deployment is necessary but not sufficient for data security. Governance is the operational layer that ensures data protection is maintained as the AI platform scales across users, use cases, and data sources.[2]
Six governance components define a complete private AI governance framework. First, data access controls: role-based access to the knowledge layer. No user queries data beyond their authorisation level. Every access event is logged against the user identity. Second, query audit trail: every query by every user is logged with timestamp, user identity, query content, and output. Third, output controls: for high-sensitivity outputs including MNPI-adjacent analysis and unpublished trial data synthesis, output review and approval before distribution. Fourth, knowledge layer update controls: validation and approval workflow for new data sources ingested into the knowledge layer. Fifth, model governance: version control for the deployed LLM, validation before model updates, and documentation of model version in all output metadata. Sixth, incident response: a defined process for suspected unauthorised access, data breach, or AI output misuse, with escalation paths and notification obligations under applicable breach notification regulations.[9]
9. How Fast Can Your Team Move to Private AI Deployment with Knolens?
Moving to private AI deployment does not require a lengthy infrastructure build or a bespoke architecture engagement. Knolens ships as a pre-built private AI platform with deployment-ready configurations for private cloud, on-premise, and air-gapped environments. The LLM-agnostic architecture means your team is not waiting for a vendor to build a custom private version of a cloud-hosted product. The private deployment capability is already part of the platform. [9]
Most pharma organisations complete the transition from public cloud AI tools to a live Knolens private deployment within six to eight weeks for their primary use case. Here is what that looks like.
Sprint 1, Weeks 1 to 2, Data risk audit and classification: Knolens onboarding begins with a structured data classification exercise using the four-tier framework built into the platform. For each current AI use case across your organisation, the data category is assessed, covering Class 1 public data through to Class 4 restricted data, and the appropriate deployment model is identified. This exercise frequently surfaces confidential clinical and commercial data that is currently being processed through public AI APIs without central IT or legal awareness. No internal audit team required. Knolens's classification templates do the heavy lifting. [8]
Sprint 2, Weeks 3 to 4, Private infrastructure configuration: For Class 3 and Class 4 use cases, the Knolens knowledge layer is deployed in the selected private environment, whether private cloud, on-premise server infrastructure, or an air-gapped enclave. Open-weight models such as Llama or Mistral are deployed locally as the inference layer. No external API calls are configured. The governance framework, covering role-based access controls, query audit trail, and output review workflows, is activated. For FDA-regulated use cases, the 21 CFR Part 11 validation package is pre-built and ready for review.
Sprint 3, Weeks 5 to 6, First live use case and user onboarding: The first private AI use case goes live, typically a clinical intelligence or competitive intelligence workflow that was previously running on a public API. Users are onboarded to the private platform. Data classification policy is communicated across functions. Public cloud AI tool access is restricted for Class 3 and Class 4 data categories. The incident response procedure is configured and tested.
From Sprint 3 onward, Knolens runs as a continuously governed private AI environment. Knowledge layer updates are ingested via controlled pipelines configured for your security requirements. Model updates are managed through the Knolens versioning framework with validation before deployment. Every query, every output, and every knowledge layer update is logged in the tamper-evident audit trail. The private deployment is not a constrained version of Knolens. It is the full platform, operating within your security perimeter. [2]
Conclusion
For pharma organisations where the data processed by AI systems includes unpublished clinical results, regulatory strategy, pipeline intelligence, and patient data, private AI deployment is not a preference. It is a data governance requirement that follows directly from the nature of the data and the legal obligations that apply to it. McKinsey estimates that 30 to 40% of all AI workloads globally will be influenced by sovereignty requirements, representing a market of $500 to $600 billion by 2030. [2] Pharma is disproportionately represented in that figure.
Pienomial's Knolens platform is built for private AI platform deployment from the architecture up, with a LLM agnostic AI platform design that enables full on-premise or air-gapped operation using locally hosted open-weight models, and a governed knowledge graph that provides intelligence capabilities without requiring external API calls. For pharma organisations that need AI to be both capable and compliant, the architecture choice starts here. [9] CTA: Book a Private Deployment Architecture Consultation with Pienomial.
